CDTX

Cidara Therapeutics (CDTX) is a biotechnology company developing next-generation immunotherapies through its Cloudbreak platform.

The company’s lead candidate, CD388, aims to provide long-lasting protection against influenza with a single dose and has shown promising results in clinical trials.

Although not yet profitable, Cidara’s innovative approach to antiviral and oncology treatments positions it as a potential breakthrough player in the biotech sector.